Researchers conducted a simulation study to determine the optimal age to discontinue long-term surveillance of low-risk intraductal papillary mucinous neoplasms (IPMNs). Using a markov model and clinical cohort data, they calculated the cost-effectiveness of continued versus discontinued surveillance at different ages. They found that the optimal age to stop surveillance varied based on sex and IPMN types, with suggested ages ranging from 70 to 84 years. The study emphasized the importance of considering individual factors, such as comorbidity levels, in the decision-making process for IPMN surveillance.
Journal Article by Hamada T, Oyama H (…) Fujishiro M et 8 al. in Gut
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.